AAN

Apr 29, 2024

VALTOCO, a nasal spray formulation of diazepam, offers enhanced convenience and simplicity for managing seizure clusters, effectively meeting a crucial gap in epilepsy care. This attribute not only empowers individuals to manage their treatment autonomously but also offers reassurance and assistance to caregivers ...

Apr 29, 2024

XEN1101, marks a significant leap forward in the realm of precision medicine for drug-resistant epilepsy, as unlike current treatments that necessitate gradual dosage adjustments, XEN1101 offers the advantage of safe initiation at optimal dosage right from the start.  XEN1101 unveils compelling efficacy wi...

Apr 29, 2024

STACCATO alprazolam, an experimental drug-device amalgamation, heralds a notable progression in epilepsy therapy. Harnessing the STACCATO delivery technology signifies a paradigm shift by facilitating swift seizure cessation within a mere 90 seconds. This achievement is made possible through a handheld inhaler dev...

Apr 26, 2024

AB-1005 represents a pioneering gene therapy utilizing an adeno-associated viral vector serotype 2 (AAV2) to deliver the human glial cell line-derived neurotrophic factor (GDNF) transgene directly into the brain. This innovative technique allows for precise and sustained expression of GDNF, offering promising ther...

Apr 26, 2024

LIBERVANT, a diazepam buccal formulation based on PharmFilm technology serves as a beacon of hope, offering convenient alternatives to existing device-based products, for managing acute repetitive seizure emergencies in young patients. LIBERVANT utilizes "fast-melt strips" for "buccal delivery of...

Apr 26, 2024

ABBV-951, an innovative investigational drug developed by AbbVie, offers hope for patients with advanced Parkinson's disease by providing continuous subcutaneous delivery of carbidopa and levodopa prodrugs, aiming to address motor fluctuations more effectively than oral medication. Leveraging its small molecule...

Apr 26, 2024

DAXXIFY (daxibotulinumtoxinA) injection represents a novel approach to treating cervical dystonia in adults and addressing moderate to severe glabellar lines associated with muscle activity, offering potential relief and aesthetic enhancement for patients. Powered by Revance's innovative Peptide Exchange Techno...

Apr 26, 2024

Inhibikase Therapeutics’ lead product candidate, Risvodetinib (IkT-148009), represents a novel therapeutic approach in the treatment of Parkinson’s disease. Unlike traditional treatments that focus on managing symptoms, Risvodetinib targets the underlying biological mechanisms driving disease progression. Risvo...

Apr 26, 2024

Ocrelizumab proves superior to first-line therapies in early RRMS, promoting better outcomes. Long-term data spanning a decade validate Ocrelizumab’s sustained efficacy and safety across MS stages, enhancing patient management. At the 2024 American Academy of Neurology conference, significant findings were ...

Apr 26, 2024

DAYVIGO (lemborexant) is an orexin receptor antagonist approved for treating adult patients with insomnia, who experience challenges with sleep onset and/or maintenance. It has received approval for insomnia treatment in over 15 countries, such as Japan, the United States, Canada, Australia, and various Asian nati...